Transthyretin Amyloid Cardiomyopathy: Literature Review and Red-Flag Symptom Clusters for Each Cardiology Specialty
ESC Heart Failure · 01.04.2025 · 12 (2) · 955-967
DOI: 10.1002/ehf2.15016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 21.08.2024. Verfasst von Yasuhiro Izumiya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Cardiology, Disease Management. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Japan Inc., Pfizer Japan.
Abstract (Originalsprache)
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non-specificity of initial symptom manifestation and insufficient awareness among treating physicians, approximately one-third of patients with ATTRwt-CM are initially misdiagnosed with other cardiac diseases. Although heart failure (HF) is the most common initial manifestation of ATTRwt-CM, observed in nearly 70% of affected patients, patients may also present with other cardiologic symptoms, such as atrial fibrillation (AF) and aortic stenosis (AS). This non-specific and diverse nature of the initial ATTRwt-CM presentation indicates that various cardiology subspecialties are involved in patient diagnosis and management. Standard guideline-directed pharmacological treatment for HF is not recommended for patients with ATTRwt-CM because of its limited effectiveness. However, no established algorithms are available regarding HF management in this patient population. This literature review provides an overview of the red flags for ATTRwt-CM and research findings regarding HF management in this patient population. In addition to commonly recognized red flags for ATTRwt-CM (e.g., HF, AF and severe AS), published literature identified potential red flags such as coronary microvascular dysfunction. For HF management in patients with ATTRwt-CM, the use of mineralocorticoid receptor antagonists (MRAs) was reported as a well-tolerated option associated with a low discontinuation rate and reduced mortality. Although there is no concrete evidence for recommendations against sodium-glucose cotransporter 2 inhibitor (SGLT2i) administration, research supporting its use is limited to small-scale studies. Robust evidence is lacking for AF ablation, implantable cardioverter-defibrillators and cardiac resynchronization therapy. Based on the published findings and our clinical experience as Japanese ATTRwt-CM experts, red-flag symptom clusters for each cardiology specialty (HF, arrhythmia and ischaemia/structural heart disease) and a treatment scheme for HF management are presented. As this research area remains at an exploratory stage, our observations would require further discussion among experts worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, Japan.
- Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
- Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
- Pfizer Japan Inc., Tokyo, Japan.
Förderung
- Pfizer Japan Inc.
- Pfizer Japan
Zitieren
APA
Izumiya, Y., Kubo, T., Endo, J., Takashio, S., Minamisawa, M., Hamada, J., Ishii, T., Abe, H., Konishi, H., & Tsujita, K. (2025). Transthyretin Amyloid Cardiomyopathy: Literature Review and Red-Flag Symptom Clusters for Each Cardiology Specialty. ESC Heart Failure, 12(2), 955-967. https://doi.org/10.1002/ehf2.15016
Vancouver
Izumiya Y, Kubo T, Endo J, Takashio S, Minamisawa M, Hamada J, et al. Transthyretin Amyloid Cardiomyopathy: Literature Review and Red-Flag Symptom Clusters for Each Cardiology Specialty. ESC Heart Failure. 2025;12(2):955-967. doi:10.1002/ehf2.15016
BibTeX
@article{Izumiya2025,
author = {Izumiya, Yasuhiro and Kubo, Toru and Endo, Jin and Takashio, Seiji and Minamisawa, Masatoshi and Hamada, Jun and Ishii, Tomonori and Abe, Hajime and Konishi, Hiroaki and Tsujita, Kenichi},
title = {Transthyretin Amyloid Cardiomyopathy: Literature Review and Red-Flag Symptom Clusters for Each Cardiology Specialty},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {2},
pages = {955--967},
doi = {10.1002/ehf2.15016}
}
EUVIMED